Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Julie Lamb
How Blockchain is Reshaping Supply Chains Beyond Finance
Have you ever wondered about the true potential of blockchain technology beyond its association with finance? Blockchain offers transparency, security, and efficiency, revolutionizing processes and unlocking new opportunities for businesses worldwide. Hence, the expected growth trajectories in the coming years. Below we look at how these benefits can provide advantages to companies adopting blockchain tech beyond pure financial applications.
The Julie Lamb Outfit Barmy Jarmies Tour
Preview the new Eventfinda Where: Spaceship, 118 Karamu Road, Hastings, Hawke's Bay / Gisborne Restrictions: All Ages Licensed Ticket Information: Pay what you want! SAY WUT!?: $0.00 Door Sales Only Additional fees may apply That's it! We manage automatic weekly payments until you're paid off. Full purchase details can be viewed anytime online. You will need To be over 18 years old Visa/Mastercard payment NZ drivers licence or passport First instalment paid today Learn more about how it works.
3 Biotech Stocks Analysts Say Are Market Winners
There are always new growth opportunities on the rise in the gainful biotech market. The real question is which drug maker is worth the risk. After all, rewards in the healthcare market can prove to be not only substantial, but there’s the added benefit of investing in a biotech company that is transforming patient’s lives. Here, we turn to the TipRanks’ Stock Screener investor tool to get a clear sense of biotech outlooks.
Word on the Street: 3 Software Stocks Ready to Pop
Dubbed ‘the father of value investing,’ Ben Graham once quipped: “Investors should purchase stocks like they purchase groceries, not like they purchase perfume.” We used the TipRanks’ Daily Analyst Ratings tool and found three stocks under $50 that have received buy recommendations in the last three days from analysts. In the next 12 months, analysts bet these 3 ‘buy’ names have room to run at least 20% more. Specifically, we sourced software stocks.
Apple Inc. (AAPL) AI Brand Just Got Stronger Thanks to New Talent Recruit, Says Gene Munster
Former head of Artificial Intelligence (AI) and Search of Google John Giannandrea is now joining the big Apple Inc.
Dynavax Technologies (DVAX) Poses Bullish Risk/Reward into Upcoming SD-101 Data
Dynavax Technologies (NASDAQ:DVAX) lead oncology product candidate SD-101 flashes favorable risk/reward heading into data to be released at two key conferences: American Association for Cancer Research (AACR) and American Society of Clinical Oncology (ASCO); one bull is counting on it.RBC Capital analyst Brian Abrahams believes this data will be “key” and between SD-101 potential coupled with momentum around Hepatitis B vaccine with “solid […] floor,” there is more than one reason to bet on...
Dynavax Technologies Corporation (DVAX) Draws a Price Target Hike on Back of Big Short-Term Upside Prospects - Smarter Analyst
Dynavax Technologies Corporation (NASDAQ:DVAX) just earned itself even more bullish confidence from Cantor analyst Elemer Piros on back of its 2017 performance.Specifically, the analyst sees meaningful upside prospects waiting in the wings for this biotech firm: from DVAX’s first commercial product HEPLISAV-B launching in January to immune-oncology program SD-101 data coupled with Keytruda due in the first half of this year at a key oncology conference.Spotlighting these catalysts as crucial...
Omeros Corporation (OMER): Analyst Believes HSCT-TMA Drug Poised to Become Primary Value Driver - Smarter Analyst
Omeros Corporation (NASDAQ:OMER) lead drug OMS721 is making clinical strides- and a bull is taking notice. Notably, patients in an ongoing Phase 2 trial experienced better overall survival in hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) after taking OMER’s treatment.
All Signs Point to Booming 4Q Backdrop for PC Supply Chain: Advanced Micro Devices, Inc. (AMD) and NVIDIA Corporation (NVDA)
The PC supply chain is looking good to Susquehanna analyst Christopher Rolland, who sees a favorable fourth quarter backdrop. Why? “Buyers desire better CPUs, discrete GPUs, and SSDs, all constructive trends for the PC supply chain overall in 4Q17,” writes Rolland. Highlighting key takeaways from the firm’s PC-SIGnals data report for leading semiconductor players, the analyst may remain on the sidelines on chip giant like Advanced Micro Devices, Inc.
Adamis Pharmaceuticals Corp (ADMP): Analyst Sees Meaningful Revenue Gains Waiting in the Wings for Sympjepi Asset
Adamis Pharmaceuticals Corp (NASDAQ:ADMP) shares were shooting up almost 9% yesterday following the news that the drug maker had submitted its prior approval supplement (PAS) with the FDA for the pediatric version of epinephrine auto-injector Symjepi. This version of Symjepi is designed to treat patients between 33 and 65 pounds, different from the original intended to treat patients weighing 66 pounds or greater.
Analysts Chime in on Celgene Corporation (CELG) Crohn's Dud and Gilead Sciences, Inc. (GILD) Winning FDA Nod for Yescarta
Celgene Corporation (NASDAQ:CELG) is getting hammered 6% in pre-market trading today after breaking the bad news that its main mongersen trial, REVOLVE was getting the axe. This Crohn’s Disease asset met its end after the results of an interim futility analysis that spelled out shortfalls in effectiveness. Top analyst Eric Schmidt at Cowen acknowledges the bitter pill of the discontinued trial is certainly “disappointing,” but he for one is none too surprised by an outcome that missed the boat.
BTIG Positive on LendingClub Corp (LC) Following Analyst Meeting
Yesterday, LendingClub Corp (NYSE:LC) executives CEO Scott Sanborn, CFO Tom Casey, and COO Sameer Gulati held an analyst meeting in New York City to discuss progress in gaining additional investors to the fintech firm’s marketplace platform, next steps for its funding mix, and what it really means for LC’s investment fund’s first month revealing a negative return since it began in 2011.
Fund Manager Kevin D Eng Boosts Position in Valeant Pharmaceuticals Intl Inc (VRX), Initiates Stakes in Facebook Inc (FB), Alphabet Inc (GOOGL)
Kevin D Eng of the $2 billion Colombus Hill Management fund has made some intriguing shifts in his Q1 portfolio including boosting his position in controversial pharma Valeant Pharmaceuticals Intl Inc (NYSE:VRX) and initiating stakes in key e-stocks Facebook Inc (NASDAQ:FB) and Alphabet Inc (NASDAQ:GOOGL). Let’s get some background insights into Kevin D Eng and his fund first before we examine these moves further.
Keep Your Eyes on These Biotech Players: CytRx Corporation (CYTR), Synergy Pharmaceuticals Inc (SGYP)
With CytRx Corporation (NYSE:CYTR) shares on the move and Synergy Pharmaceuticals Inc (NASDAQ:SGYP) raring up for a strategically executed launch for its CIC drug Trulance, analysts see these players as ones to watch in the biotech sphere. H.C. Wainwright largely sees an upcoming rolling NDA for CytRX’s Soft Tissue Sarcoma cancer drug Aldox as an encouraging step forward while BTIG highlights “meaningful” sales potential for Trulance on back of discussions with management.
Avoid These 3 Stocks like the Plague: Netflix, Inc. (NFLX), Amazon.com, Inc. (AMZN), Tesla Inc (TSLA)
I had a manager at a firm I used work with. This guy had been in the investment racket for what seems like forever. He was always available to give young brokers advice on stock selection. He would refer to stocks that carried too much risk as “chocolate covered hand grenades.” They looked enticing but sooner or later were guaranteed to blow up in your face. Coming of age in the business during the Tech Bubble of the mid-1990s, I learned a lot about ridiculous valuations.
World’s Smartest Billionaire Jim Simons Boosts Positions in Advanced Micro Devices, Inc. (AMD) and Gilead Sciences, Inc. (GILD), Takes Profits on NVIDIA Corporation (NVDA) - Smarter Analyst
Nicknamed “the world’s smartest billionaire” by the Financial Times, Jim Simons founded the highly successful $63 billion Renaissance Technologies fund. According to recently-released 13F forms filed with the SEC, we can see that in Q4 the fund upped its Advanced Micro Devices, Inc. (NASDAQ:AMD) and Gilead Sciences, Inc. (NASDAQ:GILD) positions but cut back its exposure to NVIDIA Corporation (NASDAQ:NVDA).
Galena Biopharma Inc (GALE) Hires Canaccord Genuity to Advise on Strategic Alternatives
Galena Biopharma Inc (NASDAQ:GALE) announced it has engaged Canaccord Genuity, Inc. as its financial advisor to assist in the previously announced strategic alternative review process. Potential strategic alternatives may include a sale of the company, a business combination, a merger or reverse merger with another party, continuing to advance the clinical programs as a stand-alone entity, and a license or other disposition of corporate assets of the Company.
Stock Update (NASDAQ:MU): Micron Technology, Inc. Introduces The Micron Enterprise 5100 Series SATA SSD Family
Micron Technology, Inc. (NASDAQ:MU) introduced the Micron® Enterprise 5100 Series SATA solid state drive (SSD) family, enabling future-focused data storage platforms to meet the combined demands of performance, capacity and enterprise-class reliability. Micron’s 5100 Series Enterprise SATA SSDs provide IT with an easy migration to bridge the infrastructure divide to tomorrow’s all flash data center.
Cowen Defends Dynavax Technologies Corporation (DVAX) Following FDA Setback
In a research report issued this morning, Cowen Phil Nadeau reiterated an Outperform rating on shares of Dynavax Technologies Corporation (NASDAQ:DVAX), with a price target of $45, following the news that the FDA had cancelled its upcoming ADCOM meeting for the company’s Hepatitis-B vaccine, sending shares down nearly 32% on Friday.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Julie
Contact Julie, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack